In the current study, we demonstrated that SLAMF7 ligation with ligands of tumor cells or clinical-grade monoclonal antibody elotuzumab could enhance antitumor cytotoxicity in DNT by promoting cell degranulation. Here, SLAMF7 is linked to neoplasm.